Scarica l'app Stockscreener
54.96
3.38%
-1.925
Dopo l'orario di chiusura:
54.32
-0.64
-1.16%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$56.88
Aprire:
$57.61
Volume 24 ore:
500.19K
Relative Volume:
0.54
Capitalizzazione di mercato:
$1.05B
Reddito:
$90.12M
Utile/perdita netta:
$-276.06M
Rapporto P/E:
-37.64
EPS:
-1.46
Flusso di cassa netto:
$-193.47M
1 W Prestazione:
-1.22%
1M Prestazione:
+10.16%
6M Prestazione:
+8,957%
1 anno Prestazione:
+3,883%
Intervallo 1D:
$53.73
$57.61
Intervallo di 1 settimana:
$52.91
$58.64
Portata 52W:
$0.432
$62.95
Nektar Therapeutics Stock (NKTR) Company Profile
Nome
Nektar Therapeutics
Settore
Industria
Telefono
(415) 482-5300
Indirizzo
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Confronta NKTR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
54.96 | 1.09B | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-24 | Reiterato | BTIG Research | Buy |
| 2025-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2025-04-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-03-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Iniziato | B. Riley Securities | Buy |
| 2024-12-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-04 | Iniziato | Piper Sandler | Overweight |
| 2024-09-30 | Ripresa | BTIG Research | Buy |
| 2024-06-28 | Iniziato | Rodman & Renshaw | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-11-09 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-02-24 | Downgrade | Jefferies | Hold → Underperform |
| 2022-08-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Ripresa | Jefferies | Hold |
| 2022-04-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-03-15 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-15 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-03-14 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Downgrade | Stifel | Buy → Hold |
| 2022-03-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Iniziato | BofA Securities | Neutral |
| 2021-06-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-02-22 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-09-14 | Iniziato | JP Morgan | Neutral |
| 2020-06-10 | Downgrade | CFRA | Hold → Sell |
| 2020-05-12 | Reiterato | H.C. Wainwright | Neutral |
| 2020-04-22 | Iniziato | The Benchmark Company | Buy |
| 2020-03-30 | Aggiornamento | Goldman | Sell → Neutral |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-08 | Downgrade | Goldman | Buy → Sell |
| 2019-08-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Downgrade | Jefferies | Buy → Hold |
| 2019-08-09 | Downgrade | Mizuho | Buy → Neutral |
| 2019-03-15 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-06-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Reiterato | H.C. Wainwright | Buy |
| 2018-04-20 | Iniziato | Seaport Global Securities | Buy |
| 2018-04-13 | Ripresa | Piper Jaffray | Overweight |
| 2018-04-06 | Reiterato | Mizuho | Buy |
| 2018-04-02 | Ripresa | H.C. Wainwright | Buy |
Mostra tutto
Nektar Therapeutics Borsa (NKTR) Ultime notizie
A Look at Nektar Therapeutics's Valuation Following FDA Fast Track Win for Lead Eczema Drug - simplywall.st
Evaluating Nektar Therapeutics with trendline analysisMarket Risk Report & Capital Efficiency Focused Ideas - newser.com
Litigation Delay Challenges Eli Lilly's (LLY) Legal Proceedings - GuruFocus
Is Nektar Therapeutics stock a good choice for value investorsJuly 2025 Price Swings & Verified Stock Trade Ideas - newser.com
Best data tools to analyze Nektar Therapeutics stock2025 Macro Impact & Breakout Confirmation Trade Signals - newser.com
Using economic indicators to assess Nektar Therapeutics potentialTrade Analysis Summary & Free High Return Stock Watch Alerts - newser.com
Will Nektar Therapeutics stock benefit from AI adoptionJuly 2025 Volume & Growth Focused Stock Reports - newser.com
Why retail investors pile into Nektar Therapeutics stock2025 Price Momentum & Advanced Technical Signal Analysis - newser.com
Why Nektar Therapeutics Rippled Higher This Week - MSN
Forecasting Nektar Therapeutics price range with options data2025 Market Overview & Technical Confirmation Alerts - newser.com
How Investors Are Reacting To Nektar Therapeutics (NKTR) Securing FDA Fast Track For Eczema Drug Candidate - simplywall.st
FDA Fast Track for Eczema Therapy Could Be a Game Changer for Nektar Therapeutics (NKTR) - Yahoo Finance
Nektar Therapeutics (NKTR): Assessing Valuation After a Strong Multi-Month Share Price Rally - Yahoo Finance
This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street - AOL.com
Custom strategy builders for tracking Nektar TherapeuticsVolume Spike & Expert Curated Trade Setups - newser.com
Quantitative breakdown of Nektar Therapeutics recent moveQuarterly Portfolio Report & High Accuracy Trade Signal Alerts - newser.com
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September - MSN
Wealth Enhancement Advisory Services LLC Reduces Stake in Nektar Therapeutics $NKTR - MarketBeat
Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today - MSN
Nektar Therapeutics' (NKTR) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
What MACD and RSI say about Nektar TherapeuticsJuly 2025 Fed Impact & Smart Money Movement Tracker - newser.com
Moderate to Severe Atopic Dermatitis Pipeline Drugs Insights Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight - The Globe and Mail
How Nektar Therapeutics (ITH0) stock responds to job market shiftsNew Guidance & Reliable Price Breakout Alerts - newser.com
Sector ETF performance correlation with Nektar Therapeutics2025 Technical Patterns & AI Driven Price Predictions - newser.com
Gainplan LLC Buys New Shares in Nektar Therapeutics $NKTR - MarketBeat
Public Employees Retirement System of Ohio Sells 121,001 Shares of Nektar Therapeutics $NKTR - MarketBeat
Nektar Therapeutics (NKTR): Examining Valuation After Breakthrough Eczema Drug Trial Results Spark Investor Interest - Sahm
How Nektar Therapeutics (ITH0) stock reacts to weak economyDividend Hike & Real-Time Stock Movement Alerts - newser.com
What analysts say about Nektar Therapeutics stockSwing Trading Watchlist & Build Wealth With Expert Timing Advice - earlytimes.in
Real time social sentiment graph for Nektar TherapeuticsTrade Entry Report & Fast Exit and Entry Strategy Plans - newser.com
Is a relief rally coming for Nektar Therapeutics holdersTrade Entry Summary & Advanced Swing Trade Entry Plans - newser.com
How analysts rate Nektar Therapeutics stock today2025 Support & Resistance & Long-Term Safe Return Strategies - newser.com
Nektar Therapeutics Azioni (NKTR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):